Roche dumps its PhI­II PI3K ef­fort on taselis­ib af­ter re­searchers track poor sur­vival edge, harsh side ef­fects for breast can­cer

CHICA­GO — You can write off an­oth­er PI3K drug.

Roche has de­cid­ed to scrap its con­tender taselis­ib af­ter in­ves­ti­ga­tors re­port­ed a slight, 2-month pro­gres­sion …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER